TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›NRXS›Financials
Annual statements · SEC XBRL · FY2022 – FY2025

Neuraxis, INC (NRXS) financials

Income statement

Neuraxis, INC (NRXS) income statement, annual, from SEC filings
Fiscal yearFY2022FY2023FY2024FY2025
Revenue$2.68M$2.46M$2.69M$3.57M
Revenue growth—-8.4%9.2%32.9%
Gross profit$2.39M$2.16M$2.32M$3.01M
Gross margin88.9%87.7%86.5%84.2%
Operating income-$3.37M-$6.66M-$7.16M-$7.83M
Operating margin-125.6%-270.9%-266.5%-219.4%
Net income-$4.78M-$14.6M-$8.24M-$7.80M
Net margin-178.0%-594.6%-306.8%-218.5%
EPS (diluted)-$2.77-$4.50-$1.22-$0.95

Cash flow

Neuraxis, INC (NRXS) cash flow, annual, from SEC filings
Fiscal yearFY2022FY2023FY2024FY2025
Operating cash flow-$2.30M-$6.69M-$6.10M-$6.43M
Capital expenditures$1.39K$30.8K$27.8K$31.1K
Free cash flow-$2.30M-$6.72M-$6.13M-$6.46M

Balance sheet

Neuraxis, INC (NRXS) balance sheet, annual, from SEC filings
Fiscal yearFY2022FY2023FY2024FY2025
Cash & equivalents$254K$78.6K$3.70M$4.97M
Total assets$1.48M$509K$4.76M$6.40M
Total liabilities$7.05M$1.91M$2.69M$3.00M
Long-term debt$228K———
Shareholders' equity-$5.57M-$1.40M$2.07M$3.40M
Retained earnings-$33.9M-$48.6M-$56.8M-$64.6M
Shares (wtd avg diluted)2.00M3.25M6.92M9.08M

Every figure is extracted from Neuraxis, INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is Neuraxis, INC's annual revenue?
Neuraxis, INC (NRXS) reported $3.57M of revenue for fiscal year 2025 — up 32.9% from $2.69M in FY2024, per its annual report filed with the SEC.
Is Neuraxis, INC profitable?
Not in FY2025 — NRXS reported a net loss of $7.80M, per SEC filings.
What is Neuraxis, INC's free cash flow?
-$6.46M in FY2025 (operating cash flow -$6.43M minus $31.1K of capital expenditures), from the SEC cash-flow statement.
Does NRXS pay a dividend?
Neuraxis, INC reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full NRXS analysis — verdict, score & filings →Is NRXS a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.